Matteo Ruggiu
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Matteo Ruggiu is an Associate Professor at St. John's University, located in the United States. His research focuses on the interplay between RNA editing and alternative splicing, particularly in relation to voltage-gated calcium channels and their associated pathologies. He has recently published articles exploring the biological properties of CaV1.3 channels and the implications of alternative splicing in immune mediators within the context of cancer.
Recent Grants
Grant: Close
Investigating the Mechanism Regulating Alternative Splicing of Neural Agin: A Novel Therapeutic Entry Point for Congenital Myasthenic Syndrome
Open Date: 2016-06-01
Close Date: 2021-05-31
Grant: Close
Neuronal RNA-binding protein function studied through analysis of the Nova paraneoplastic neurologic disease antigen
Open Date: 2000-05-01
Close Date: 2003-04-30
Grant: Close
Neuronal RNA-binding protein fucntion studied through analysis of the nova paraneoplastic neurological disease antigen.
Open Date: 2000-04-01
Close Date: 2002-03-31
Grant: Close
Neuronal RNA-binding protein function studied through analysis of the nova paraneoplastic neurological disease antigen.
Open Date: 2000-04-01
Close Date: 2002-03-31
Articles (8)
Year:
2026
Year:
2026
Year:
2025
Voltage‐gated calcium channels (VGCCs) are multi‐subunit ion channel proteins that control and regulate a wide array of physiological processes. Their dysfunction has been implicated in several neurological, cardiac, psychiatric, endocrine, oncogenic, and muscular disorders. The diverse and specialized cellular functions involving VGCC‐mediated calcium signaling stem from two primary mechanisms: differential and cell‐specific expression of pore‐forming (α1) and auxiliary subunit genes, and extensive alternative splicing of their pre‐mRNA. All the 10 α1‐encoding genes undergo alternative splicing to generate a wide array of cell‐specific CaV variants with distinct biophysical, pharmacological, and protein–protein interaction properties. This proteomic diversity and the associated cell‐specific expression signature of CaV splice variants are tightly regulated by trans ‐acting splicing factors—RNA‐binding proteins that control the inclusion or skipping of alternatively spliced exons during post‐transcriptional pre‐mRNA processing. The discovery that several channelopathies are caused by aberrant splicing due to genetic mutations in either cis ‐acting binding elements on the pre‐mRNA or in core splicing machinery components highlights the crucial role of alternative splicing in VGCC‐related pathologies. These insights have opened new therapeutic avenues, as targeting the alternative splicing of disease‐associated specific exons has recently emerged as a novel, promising treatment for neurodevelopmental disorders and channelopathies associated with splicing dysfunction.
Year:
2025
In mammals, neuromuscular synapses rely on clustering of acetylcholine receptors (AChRs) in the muscle plasma membrane, ensuring optimal stimulation by motor neuron-released acetylcholine neurotransmitter. This clustering depends on a complex pathway based on alternative splicing of Agrin pre-mRNAs by the RNA-binding proteins Nova1/2. Neuron-specific expression of Nova1/2 ensures the inclusion of small “Z” exons in Agrin , resulting in a neural-specific form of this extracellular proteoglycan carrying a short peptide motif that is required for binding to Lrp4 receptors on the muscle side, which in turn stimulate AChR clustering. Here we show that this intricate pathway is remarkably conserved in Ciona robusta, a non-vertebrate chordate in the tunicate subphylum. We use in vivo tissue-specific CRISPR/Cas9-mediated mutagenesis and heterologous “minigene” alternative splicing assays in cultured mammalian cells to show that Ciona Nova is also necessary and sufficient for Agrin Z exon inclusion and downstream Lrp4-mediated AChR clustering. We present evidence that, although the overall pathway is well conserved, there are unexpected differences in Nova structure-function between Ciona and mammals. We further show that, in Ciona motor neurons, the transcription factor Ebf is a key activator of Nova expression, thus ultimately linking this RNA switch to a conserved, motor neuron-specific transcriptional regulatory network.
Year:
2025
Interferon-gamma (IFN-γ) is a critical cytokine that plays a pivotal role in immune system regulation. It is a key mediator of both cellular defense mechanisms and antitumor immunity. As the sole member of the type II interferon family, IFN-γ modulates immune responses by activating macrophages, enhancing natural killer cell function, and regulating gene expression across multiple cellular processes. Alternative splicing is a post-transcriptional gene expression regulatory mechanism that generates multiple mature messenger RNAs from a single gene, dramatically increasing proteome diversity without the need of a proportional genome expansion. This process occurs in 90–95% of human genes, with alternative splicing events allowing for the production of diverse protein isoforms that can have distinct—or even opposing—functional properties. Alternative splicing plays a crucial role in cancer immunology, potentially generating tumor neoepitopes and modulating immune responses. However, how alternative splicing affects IFN-γ’s activity is still poorly understood. This review explores how alternative splicing regulates the expression and function of both upstream regulators and downstream effectors of IFN-γ, revealing complex mechanisms of gene expression and immune response modulation. Key transcription factors and signaling molecules of the IFN-γ pathway are alternatively spliced, and alternative splicing can dramatically alter IFN-γ signaling, immune cell function, and response to environmental cues. Specific splice variants can enhance or inhibit IFN-γ-mediated immune responses, potentially influencing cancer immunotherapy, autoimmune conditions, and infectious disease outcomes. The emerging understanding of these splicing events offers promising therapeutic strategies for manipulating immune responses through targeted molecular interventions.
Year:
2025
In mammals, neuromuscular synapses rely on clustering of acetylcholine receptors (AChRs) in the muscle plasma membrane, ensuring optimal stimulation by motor neuron-released acetylcholine neurotransmitter. This clustering depends on a complex pathway based on alternative splicing of Agrin mRNAs by the RNA-binding proteins Nova1/2. Neuron-specific expression of Nova1/2 ensures the inclusion of small "Z" exons in Agrin, resulting in a neural-specific form of this extracellular proteoglycan carrying a short peptide motif that is required for binding to Lrp4 receptors on the muscle side, which in turn stimulate AChR clustering. Here we show that this intricate pathway is remarkably conserved in Ciona robusta, a non-vertebrate chordate in the tunicate subphylum. We use in vivo tissue-specific CRISPR/Cas9-mediated mutagenesis and heterologous "mini-gene" alternative splicing assays in cultured mammalian cells to show that Ciona Nova is also necessary and sufficient for Agrin Z exon inclusion and downstream AChR clustering. We present evidence that, although the overall pathway is well conserved, there are some surprising differences in Nova structure-function between Ciona and mammals. We further show that, in Ciona motor neurons, the transcription factor Ebf is a key activator of Nova expression, thus ultimately linking this RNA switch to a conserved, motor neuron-specific transcriptional regulatory network.
Year:
2024
Year:
2020
Collaborators (3)
Lionel Christiaen
Director, Group leader
New York University
Alessandro Mussa
Deputy Director, Director for Research
Università degli Studi di Torino
Yong Yu
Professor
St. John's University
Make your next move.
Prepare your application
Review drafts before you send them.